Home › Research › Getting a diagnosis
Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density
Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R et al.. JAMA neurology, 2015-03-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Results Of 176 patients with evaluable images, 68 patients (38%) died during the study, were autopsied, and had neuritic plaque levels determined; 25 brains (37%) were β-amyloid negative; and 43 brains (63%) were β-amyloid positive. When scans were interpreted with computed tomography images, sensitivity and specificity improved for most readers but the differences were not significant. Conclusions and relevance This study showed that flutemetamol injection labeled with radioactive fluorine 18 was safe and had high sensitivity and specificity in an end-of-life population.
What this study adds
Evidence grade: Low
This is a trial of 176 participants. This phase 3 trial found that flutemetamol injection labeled with radioactive fluorine 18 was safe and had high sensitivity and specificity for detecting neuritic plaque density in an end-of-life population. When scans were interpreted with computed tomography images, sensitivity and specificity improved for most readers but the differences were not significant.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Curtis, C., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., et al. (2015). Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA neurology. https://doi.org/10.1001/jamaneurol.2014.4144
Vancouver
Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA neurology. 2015. doi:10.1001/jamaneurol.2014.4144. PMID: 25622185.
BibTeX
@article{curtis2015-25622185,
author = {Curtis, C. and Gamez, J. E. and Singh, U. and Sadowsky, C. H. and Villena, T. and Sabbagh, M. N. and Beach, T. G. and Duara, R. and others},
title = {{Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density}},
journal = {JAMA neurology},
year = {2015},
doi = {10.1001/jamaneurol.2014.4144},
pmid = {25622185},
url = {https://doi.org/10.1001/jamaneurol.2014.4144}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Of 176 patients with evaluable images, 68 patients (38%) died during the study, were autopsied, and had neuritic plaque levels determined; 25 brains (37%) were β-amyloid negative; and 43 brains (63%) were β-amyloid positive.
- When scans were interpreted with computed tomography images, sensitivity and specificity improved for most readers but the differences were not significant.
- Conclusions and relevance This study showed that flutemetamol injection labeled with radioactive fluorine 18 was safe and had high sensitivity and specificity in an end-of-life population.
Why it matters
This phase 3 trial found that flutemetamol injection labeled with radioactive fluorine 18 was safe and had high sensitivity and specificity for detecting neuritic plaque density in an end-of-life population. When scans were interpreted with computed tomography images, sensitivity and specificity improved for most readers but the differences were not significant.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Study designopen-label trial
- Participants176
- Evidence strengthLow
How this study scored 71/100
Published in a leading specialty journal, and it is a large phase 3 trial. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A large phase 3 trial (from PubMed type “Clinical Trial, Phase III”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 176 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 334 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 25.7 citations a year over 13 year(s) since 2015 |
| Impact for its field and year | 5 / 6 | Cited 24.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 27 other studies in this library |
| Still being cited | 3 / 4 | Cited 85 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Stephen Salloway: h-index 109 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Michigan: institution h-index 2,240 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 20 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 25622185) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 71 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Later studies that cite this one
27 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Getting a diagnosis from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.